Skip to main content

Table 1 Clinicopathological information of ovarian cancer patients (n = 112)

From: Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features

Variables
 Age (years), median (range) 56 (36–74)
 Neoadjuvant chemotherapy (%) 14 (12.5%)
Histology
 High-grade serous carcinoma 95 (84.8%)
 Clear cell carcinoma 9 (8.03%)
 Endometrioid 2 (1.8%)
 Mucinous 2 (1.8%)
 Carcinosarcoma 3 (2.7%)
 Squamous 1 (0.9%)
FIGO stage (%)
 I 15 (13.4%)
 II 5 (4.5%)
 III 64 (57.1%)
 IV 28 (25.0%)
 Pre-treatment serum CA 125 (U/mL), median (range) 746.4 (10–5000)a
Residual disease (%)
  ≤ 1 cm (optimal) 88 (78.6%)
  > 1 cm (suboptimal) 24 (21.4%)
Platinum response (%)b
 Sensitive 45 (76.3%)
 Resistant 14 (23.7%)
  1. aThe upper limit of CA 125 detection is 5000
  2. bA total of 59 patients were available for platinum response assessment
  3. Abbreviations: FIGO The International Federation of Gynecology and Obstetrics, CA125 Cancer Antigen